JP2005511642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511642A5 JP2005511642A5 JP2003546936A JP2003546936A JP2005511642A5 JP 2005511642 A5 JP2005511642 A5 JP 2005511642A5 JP 2003546936 A JP2003546936 A JP 2003546936A JP 2003546936 A JP2003546936 A JP 2003546936A JP 2005511642 A5 JP2005511642 A5 JP 2005511642A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- formula
- compound
- pharmaceutically acceptable
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 7
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 7
- 229960002216 methylparaben Drugs 0.000 claims description 7
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960003415 propylparaben Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000004067 bulking agent Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 4
- 239000003755 preservative agent Substances 0.000 claims 4
- 230000002335 preservative effect Effects 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 1
- 229960001950 benzethonium chloride Drugs 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 229960004217 benzyl alcohol Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33853601P | 2001-11-30 | 2001-11-30 | |
| US60/338,536 | 2001-11-30 | ||
| US39893202P | 2002-07-26 | 2002-07-26 | |
| US60/398,932 | 2002-07-26 | ||
| PCT/IB2002/004743 WO2003045435A1 (en) | 2001-11-30 | 2002-11-13 | Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005511642A JP2005511642A (ja) | 2005-04-28 |
| JP2005511642A5 true JP2005511642A5 (enExample) | 2006-01-12 |
| JP4689959B2 JP4689959B2 (ja) | 2011-06-01 |
Family
ID=26991236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003546936A Expired - Lifetime JP4689959B2 (ja) | 2001-11-30 | 2002-11-13 | セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7378408B2 (enExample) |
| EP (1) | EP1448234B1 (enExample) |
| JP (1) | JP4689959B2 (enExample) |
| KR (1) | KR100621291B1 (enExample) |
| CN (1) | CN100502873C (enExample) |
| AR (1) | AR037595A1 (enExample) |
| AT (1) | ATE406916T1 (enExample) |
| AU (1) | AU2002348986B2 (enExample) |
| BR (1) | BRPI0214583B1 (enExample) |
| CA (1) | CA2468708C (enExample) |
| CY (1) | CY1108437T1 (enExample) |
| DE (1) | DE60228749D1 (enExample) |
| DK (1) | DK1448234T3 (enExample) |
| EA (1) | EA008503B1 (enExample) |
| ES (1) | ES2307800T3 (enExample) |
| HR (1) | HRP20040487A2 (enExample) |
| IL (2) | IL161851A0 (enExample) |
| IS (1) | IS7214A (enExample) |
| MA (1) | MA27085A1 (enExample) |
| MX (1) | MXPA04003724A (enExample) |
| NO (1) | NO334818B1 (enExample) |
| NZ (1) | NZ532208A (enExample) |
| PL (1) | PL212683B1 (enExample) |
| PT (1) | PT1448234E (enExample) |
| TN (1) | TNSN04097A1 (enExample) |
| TW (1) | TWI248363B (enExample) |
| WO (1) | WO2003045435A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20021725A1 (it) | 2002-08-01 | 2002-10-31 | Zambon Spa | Composizioni farmaceutiche ad attivita' antibiotica. |
| US20080096858A1 (en) * | 2004-04-22 | 2008-04-24 | University Of Connecticut | Method of Stabilizing Disordered Cefovecin Sodium Salt |
| EP1656930A1 (en) * | 2004-11-10 | 2006-05-17 | Basilea Pharmaceutica AG | Stabilized freeze-dried formulation for cephalosporin derivatives |
| WO2006064516A1 (en) * | 2004-12-17 | 2006-06-22 | Venus Remedies Limited | Antibiotic combinations for providing total solution to the treatment of infections |
| CA2597812C (en) * | 2005-02-14 | 2012-01-24 | Venus Remedies Limited | Parenteral combination therapy for infective conditions with drug resistant bacterium |
| ATE472996T1 (de) * | 2005-10-29 | 2010-07-15 | Intervet Int Bv | Cefquinomzusammensetzungen und verfahren zu ihrer verwendung |
| US20080103121A1 (en) * | 2006-10-30 | 2008-05-01 | Gole Dilip J | Cephalosporin derivative formulation |
| WO2009111422A2 (en) * | 2008-03-04 | 2009-09-11 | Elan Pharmaceuticals, Inc. | Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
| CN101352422B (zh) * | 2008-09-17 | 2011-04-20 | 厦门朝阳生物工程有限公司 | 河豚毒素冻干粉针制剂及其制备方法 |
| US9060926B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8849441B2 (en) | 2008-10-31 | 2014-09-30 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8793075B2 (en) | 2008-10-31 | 2014-07-29 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9050317B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8731840B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9072688B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US20110150765A1 (en) | 2008-10-31 | 2011-06-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Frozen compositions and methods for piercing a substrate |
| US9072799B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8762067B2 (en) | 2008-10-31 | 2014-06-24 | The Invention Science Fund I, Llc | Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data |
| US8725420B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8788211B2 (en) * | 2008-10-31 | 2014-07-22 | The Invention Science Fund I, Llc | Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition |
| US8545806B2 (en) | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8721583B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US9050251B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
| US9060934B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US9060931B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
| US8731841B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9050070B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US20100111857A1 (en) | 2008-10-31 | 2010-05-06 | Boyden Edward S | Compositions and methods for surface abrasion with frozen particles |
| US20140274993A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane-tazobactam pharmaceutical compositions |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| US20140274994A1 (en) * | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Stabilizing ceftolozane |
| WO2017007515A1 (en) * | 2015-07-09 | 2017-01-12 | Universal Nutrients, Llc | Pharmaceutical compositions |
| JP7020913B2 (ja) | 2015-09-07 | 2022-02-16 | 持田製薬株式会社 | アルギン酸凍結乾燥製剤 |
| EP3687993A1 (en) | 2017-09-27 | 2020-08-05 | Meiji Seika Pharma Co., Ltd. | Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof |
| EP3687992A1 (en) | 2017-09-27 | 2020-08-05 | Meiji Seika Pharma Co., Ltd. | Crystalline forms of diazabicyclooctane derivatives and production process thereof |
| CN111447924A (zh) * | 2017-09-27 | 2020-07-24 | 费多拉制药公司 | 二氮杂二环辛烷衍生物的药物形式及其制备方法 |
| GB2575261B (en) | 2018-07-02 | 2022-03-09 | Norbrook Lab Ltd | Intermediates in the synthesis of C3-substituted cephalosporins |
| CN109393004A (zh) * | 2018-09-28 | 2019-03-01 | 上海锦立保鲜科技有限公司 | 一种利用冻品自由水升华实现真空解冻的方法 |
| CN118284438A (zh) * | 2021-11-26 | 2024-07-02 | 安斯泰来制药株式会社 | 含有吲哚菁化合物的固体药物组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4002748A (en) * | 1976-01-19 | 1977-01-11 | Eli Lilly And Company | Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration |
| JPS5711909A (en) * | 1980-06-23 | 1982-01-21 | Shionogi & Co Ltd | Stable freeze-dried preparation of beta-lactam |
| JPS6045514A (ja) * | 1983-08-22 | 1985-03-12 | Shionogi & Co Ltd | 安定な抗菌性凍結乾燥製剤 |
| SE8500273D0 (sv) * | 1985-01-22 | 1985-01-22 | Leo Ab | Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder |
| US5138066A (en) * | 1987-08-14 | 1992-08-11 | Hoffmann-La Roche, Inc. | Intermediates for cephalosporins with sulfur-containing oxyimino side chain |
| NZ227842A (en) | 1988-02-05 | 1990-12-21 | Lilly Co Eli | Crystalline 2.5-hydrate form of a beta-lactam |
| CA2024587A1 (en) * | 1989-09-05 | 1991-03-06 | Bernard Ecanow | Drug delivery compositions based on biological cells or components thereof and methods |
| US6001997A (en) * | 1990-07-24 | 1999-12-14 | Bateson; John Hargreaves | Cephalosporins and homologues, preparations and pharmaceutical compositions |
| MY106399A (en) * | 1990-07-24 | 1995-05-30 | Pfizer | Cephalosporins and homologeus, preparation and pharmaceutical composition |
| US6020329A (en) * | 1990-07-24 | 2000-02-01 | Pzifer Inc. | Cephaloporins and homologues, preparations and pharmaceutical compositions |
| US5401842A (en) * | 1992-09-08 | 1995-03-28 | Bristol-Myers Squibb Company | Injectable compositions of a cephalosporin dihydrate salt |
| EP0664117A1 (de) * | 1994-01-25 | 1995-07-26 | F. Hoffmann-La Roche Ag | Liposomenlösungen |
| US5665760A (en) * | 1995-09-18 | 1997-09-09 | Sanofi Winthrop, Inc. | Lyophilized thioxanthenone antitumor agents |
| KR100312622B1 (ko) * | 1998-11-03 | 2002-02-28 | 김송배 | 생약을주성분으로한안정화된항암제조성물및그제조방법 |
| JP2001199889A (ja) * | 1999-11-11 | 2001-07-24 | Takeda Chem Ind Ltd | 縮合ピリダジン誘導体を含有してなる点鼻用剤 |
| EP1246668B1 (en) | 1999-12-01 | 2005-11-30 | Natco Pharma Limited | An rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| GB0002835D0 (en) * | 2000-02-09 | 2000-03-29 | Melvin William T | Drug resistance in cancer |
| GB0019124D0 (en) | 2000-08-03 | 2000-09-27 | Pfizer | Novel process |
| RU2237670C1 (ru) * | 2000-12-04 | 2004-10-10 | Пфайзер Продактс Инк. | Способ взаимодействия и промежуточные продукты, пригодные для получения цефалоспоринов |
-
2002
- 2002-11-12 US US10/292,343 patent/US7378408B2/en not_active Expired - Lifetime
- 2002-11-13 EA EA200400489A patent/EA008503B1/ru unknown
- 2002-11-13 NZ NZ532208A patent/NZ532208A/en not_active IP Right Cessation
- 2002-11-13 DE DE60228749T patent/DE60228749D1/de not_active Expired - Lifetime
- 2002-11-13 AT AT02781499T patent/ATE406916T1/de active
- 2002-11-13 WO PCT/IB2002/004743 patent/WO2003045435A1/en not_active Ceased
- 2002-11-13 PL PL370083A patent/PL212683B1/pl unknown
- 2002-11-13 ES ES02781499T patent/ES2307800T3/es not_active Expired - Lifetime
- 2002-11-13 KR KR1020047008097A patent/KR100621291B1/ko not_active Expired - Lifetime
- 2002-11-13 CN CNB028229258A patent/CN100502873C/zh not_active Expired - Lifetime
- 2002-11-13 DK DK02781499T patent/DK1448234T3/da active
- 2002-11-13 CA CA002468708A patent/CA2468708C/en not_active Expired - Lifetime
- 2002-11-13 EP EP02781499A patent/EP1448234B1/en not_active Expired - Lifetime
- 2002-11-13 AU AU2002348986A patent/AU2002348986B2/en not_active Expired
- 2002-11-13 MX MXPA04003724A patent/MXPA04003724A/es active IP Right Grant
- 2002-11-13 HR HR20040487A patent/HRP20040487A2/hr not_active Application Discontinuation
- 2002-11-13 IL IL16185102A patent/IL161851A0/xx unknown
- 2002-11-13 BR BRPI0214583A patent/BRPI0214583B1/pt active IP Right Grant
- 2002-11-13 JP JP2003546936A patent/JP4689959B2/ja not_active Expired - Lifetime
- 2002-11-13 PT PT02781499T patent/PT1448234E/pt unknown
- 2002-11-19 TW TW091133707A patent/TWI248363B/zh not_active IP Right Cessation
- 2002-11-28 AR ARP020104594A patent/AR037595A1/es not_active Application Discontinuation
-
2004
- 2004-04-07 IS IS7214A patent/IS7214A/is unknown
- 2004-05-06 IL IL161851A patent/IL161851A/en active IP Right Grant
- 2004-05-20 MA MA27689A patent/MA27085A1/fr unknown
- 2004-05-28 TN TNP2004000097A patent/TNSN04097A1/fr unknown
- 2004-06-01 NO NO20042271A patent/NO334818B1/no not_active IP Right Cessation
-
2008
- 2008-10-21 CY CY20081101180T patent/CY1108437T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511642A5 (enExample) | ||
| AU2017201670B2 (en) | A composition comprising an antibiotic and a dispersant or an anti-adhesive agent | |
| JP5866298B2 (ja) | 抗菌剤およびその使用法 | |
| US6017912A (en) | Topical fluoroquinolone antibiotics in an alcohol and acetone vehicle | |
| EP1175217B8 (en) | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents | |
| US11779559B2 (en) | Compositions for treating fungal and bacterial biofilms and methods of using the same | |
| US20220040306A1 (en) | Topical formulations and treatments | |
| JPH1160505A (ja) | 防腐組成物 | |
| US20040096521A1 (en) | Method and composition for treating hairy hoof warts | |
| AR018335A1 (es) | Compuesto carbapenico, agente antibacteriano que lo comprende y compuesto carbapenico util como intermediario para la obtencion del primero | |
| JP4685242B2 (ja) | ヒアルロン酸を用いた放射線膀胱炎の予防、軽減、および治療法 | |
| AU2004222664B2 (en) | Anti-microbially active diamine-based guanine derivatives | |
| KR101392285B1 (ko) | 이중층 구조를 갖는 위체류성 서방성 제제 | |
| EP1251874A1 (en) | Stabilised pharmaceutical compositions and process for their preparation comprising an antibiotic and an expectorant | |
| Kosmidis et al. | Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection | |
| US20090124632A1 (en) | Methods and kits related to the topical administration of quinolone antibiotics° | |
| RU2005130771A (ru) | Композиции и способы профилактики и лечения эндотоксин-связанных заболеваний и состояний | |
| JP2022523975A (ja) | 微生物除去 | |
| US20030073625A1 (en) | Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides | |
| US12109176B1 (en) | Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives | |
| JP2944759B2 (ja) | 抗菌性組成物 | |
| CN1682703A (zh) | 一种杀菌凝胶剂 | |
| JP6748339B2 (ja) | フィナフロキサシンおよびトリスを含む組成物 | |
| TW201010727A (en) | Pharmaceutical composition having relatively low ionic strength | |
| JPH10265391A (ja) | 外傷用組成物 |